Assessment of Augmentation Strategies to Optimize the Therapeutic Response to Mirtazapine in Major Depressio

Organon International Inc. (USA)0 个研究点目标入组 100 人开始时间: 2006年2月15日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Male or female patients between 18 and 65 years of age
•2. Diagnosis of major depression according to the Diagnostic and Statistical Manual of Mental Disorders - fourth edition (DSM-IV) (American Psychiatric Association, 1994) using the Structural Clinical Interview for DSM-IV (SCID) (Spitzer and Williams, 1988)
•3. Initial global score 18 on the first 17 items of the 24-item Hamilton Depression Rating Scale
•4. Written informed consent signed by the patient

•1. Patients who have not participated in another clinical trial in the past 30 days
•2. Evidence of suicidal tendencies
•3. Evidence of significant physical illness contraindicating the use of fluoxetine, mirtazapine, venlafaxine or bupropion, found on physical or in the laboratory data obtained during the first week of the study
•4. Mental retardation (Intelligence Quotient [IQ] lower than 80) rendering the response to investigators unreliable
•5. Pregnancy, or absence of adequate contraceptive method in women with childbearing potential
•6. Concurrent use of psychotropic medication such as neuroleptics, mood stabilizers or regular use of high doses of benzodiazepines
•7. Lack of response to fluoxetine for the present episode

发起方

Organon International Inc. (USA)